Achieve Life Sciences(ACHV) Newsfilter·2024-05-17 12:00Core Insights - Achieve Life Sciences, Inc. announced the presentation of Phase 2 ORCA-V1 trial data for cytisinicline, which showed that treatment more than doubled the likelihood of quitting vaping compared to placebo [1][2]. Company Overview - Achieve Life Sciences is focused on the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence [1][4]. - The company aims to address the smoking health crisis, with an estimated 28 million adults in the U.S. smoking combustible cigarettes and over 11 million using e-cigarettes [4]. Clinical Trial Details - The ORCA-V1 trial involved 160 daily e-cigarette users across five clinical trial locations in the U.S. Participants received 3 mg of cytisinicline three times daily or a placebo for 12 weeks, alongside standard cessation behavioral support [3]. - The trial was supported by the National Institute on Drug Abuse (NIDA) with grant funding totaling $2.8 million [3]. Product Information - Cytisinicline is a plant-based alkaloid that interacts with nicotinic acetylcholine receptors in the brain, potentially reducing withdrawal symptoms and the satisfaction associated with nicotine products [5]. - Currently, there are no FDA-approved treatments specifically for nicotine e-cigarette cessation, highlighting a significant market opportunity for cytisinicline [4].